Browsing Tag
European Respiratory Society
1 post
Winrevair slashes early PAH worsening by 76% in phase 3 Hyperion, but can it reset first-year care?
Winrevair reduced PAH clinical worsening by 76% in phase 3 Hyperion. Learn how Merck’s results could reset first-year treatment guidelines today.